Although the FDA has approved a PD-L1 IHC test as a companion diagnostic for the immunotherapeutic targeting of the PD-1/PD-L1 pathway in some neoplasms, the expression pattern of PD-1 and PD-L1 is not a good predictive biomarker for all types of cancer [24]. Here, PDCD1 is linked to neoplasm.